Showing results (41-50 of 108) with videos related to
Sort By:
Pageof 11
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|December 7, 2010
[Clinical report of combined chemotherapy with gemcitabine plus cisplatin as first-line treatment to 79 cases of advanced non-small cell lung cancer]Lin Lin, Xuezhi Hao, Junling Li, et al.Cancer Medicine|August 14, 2019
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world studyGuangjian Yang, Di Ma, Haiyan Xu, et al.Targeted Oncology|May 25, 2019
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with OsimertinibYuxin Mu, Xuezhi Hao, Ke Yang, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 12, 2013
[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment]Xin Zhang, Bin Wang, Lin Lin, et al.Asia-Pacific Journal of Clinical Oncology|October 13, 2018
Clinicopathologic characteristics and outcome of patients with different EGFR mutationsShengyu Zhou, Xingsheng Hu, Yan Wang, et al.Journal of Translational Medicine|June 1, 2022
Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLCShasha Wang, Ning Lou, Rongrong Luo, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 26, 2026
Adjuvant immunotherapy in resected non-small cell lung cancer harboring oncogenic driver alterations beyond EGFR and ALK: results from a retrospective analysisWenxin Jiang, Haiyan Xu, Junling Li, et al.Thoracic Cancer|September 14, 2022
Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrencesFei Xu, Heng-Chi Chen, Haiyan Xu, et al.Journal of Cancer Research and Clinical Oncology|January 4, 2022
Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort studyZiyi Xu, Xuezhi Hao, Ke Yang, et al.Thoracic Cancer|September 23, 2023
Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world studyYaning Yang, Guangjian Yang, Weihua Li, et al.Pageof 11